Lung Cancer Screening: New Perspective and Challenges in Europe

Cancers · 2022 · Europe

Source and licence

Authors
Jan P Van Meerbeeck, Emma O’Dowd, Brian Ward et al.
Title
Lung Cancer Screening: New Perspective and Challenges in Europe
Journal
Cancers, 2022
Licence
CC BY 4.0
Changes
Verbatim excerpts; formatting adapted

Full text retrieved 2026-10-27 from Europe PMC · PMC9099920

Licence statement of the original publication

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.

This is a review of another guideline (EU Council Recommendation on cancer screening (lung cancer screening), Council of the EU / European societies 2022). We do not reproduce that guideline's recommendations here – they belong to the original guideline.

Open the original publication →Full text on Europe PMC

Abstract

Simple Summary: Screening for lung cancer in a high-risk population has been shown to be beneficial, with reduced mortality in large randomised trials. However, the general implementation of screening is not evident and many factors have to be considered. In this paper, we will review the current status of screening for lung cancer in Europe and the many hurdles that have to be overcome. Multidisciplinary cooperation between all specialists dealing with lung cancer is required to obtain the best outcome. Hopefully, Europe’s Beating Cancer Plan will incorporate screening for lung cancer to allow general implementation by similar programmes in every European Member State. This will also provide an opportunity for further, large-scale studies to refine the inclusion of specific risk populations, diagnosis and management of screen-detected nodules.

Abstract: Randomized-controlled trials have shown clear evidence that lung cancer screening with low-dose CT in a high-risk population of current or former smokers can significantly reduce lung-cancer-specific mortality by an inversion of stage distribution at diagnosis. This paper will review areas in which there is good or emerging evidence and areas which still require investment, research or represent implementation challenges. The implementation of population-based lung cancer screening in Europe is variable and fragmented. A number of European countries seem be on the verge of implementing lung cancer screening, mainly through the implementation of studies or trials. The cost and capacity of CT scanners and radiologists are considered to be the main hurdles for future implementation. Actions by the European Commission, related to its published Europe’s Beating Cancer Plan and the proposal to update recommendations on cancer screening, could be an incentive to help speed up its implementation.

Contents of the original publication

The section headings of the original.

  • 1. Introduction
  • 2. Recruitment, Eligibility Optimisation and Participation
  • 3. Harm Minimization
  • 4. Cost Effectiveness and Add-On Health Interventions
  • 5. Incidental Findings
  • 6. Workforce/Capacity
  • 7. Quality Assurance
  • 8. The European Union (EU) and Lung Cancer Screening
  • 9. Implementation of Lung Cancer Screening in Europe
  • 10. Conclusions

A question about this guideline?

Medelix answers clinical questions from guidelines and studies – every statement with its source.

Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint